Outpace Bio
Revolutionizing Cell Therapy with Protein Design
75 employees · est. 2020 · Seattle, United States
Barinthus Biotherapeutics
Barinthus is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutic candidates.
39 employees · est. 2016 · Oxford, United Kingdom
Barinthus Biotherapeutics is the older company (2020 vs 2016); Outpace Bio is the larger of the two.
Side-by-Side Comparison
| Metric | Outpace Bio | Barinthus Biotherapeutics |
|---|---|---|
| Founded | ||
| Founded | 2020 | 2016 older |
| Headquarters | ||
| Headquarters | Seattle, United States | Oxford, United Kingdom |
| Employees | ||
| Employees | 75 larger | 39 |
| Industry | ||
| Industry | Biotechnology, Health Care, Life Sciences | Biotechnology, Health and Wellness, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Series B | Acquired |
| Total Funding | ||
| Total Funding | $199.00M | $146.66M |
| Funding Rounds | ||
| Funding Rounds | 4 | 7 |
| Services | ||
| Services | AI-powered protein design, Cell therapy development, Cytokine design for immune modulation, Safety and specificity enhancement of cell therapies, Translational models in oncology | Development of antigen-specific immunotherapies, Phase 1b/2 clinical trials, Pipeline management for autoimmune diseases and chronic viral infections, Biopharmaceutical research and development |
| Target Customers | ||
| Target Customers | Pharmaceutical companies, Biotech firms, Oncology researchers, Healthcare institutions, Academic collaborators | Patients with autoimmune and inflammatory conditions, Patients with chronic viral infections, Healthcare providers, Oncologists |
| Taxonomy | ||
| Taxonomy | Cell Therapy, Protein Design, Cellular Engineering, Solid Tumors, Immune Response, Tumor Microenvironment, Custom Biological Functions, Cellular Control Modalities, Immune Cell Therapy, Cancer Treatment, Safety And Efficacy, Clinical Validation, Diverse Cancer Indications, Cytokines | T-cell Immunotherapeutics, Chronic Infectious Diseases, Autoimmunity, Cancer Treatment, ChAdOx Technology, MVA Boost Vector, SNAP-TI Platform, SNAP-CI Platform, CD8+ T Cells, Chronic HBV Treatment, Celiac Disease Treatment, Prostate Cancer Treatment, Viral Vaccine Development, Biopharmaceutical Innovation, Immunotherapeutic Pipeline |
| Website | ||
| Website | outpacebio.com | barinthusbio.com |
About Outpace Bio
Outpace Bio, founded in 2020, is at the forefront of cell therapy innovation, leveraging advanced protein design to revolutionize treatment options, particularly targeting solid tumors. With their slogan, "Revolutionizing Cell Therapy with Protein Design", the company promises transformative advance...
About Barinthus Biotherapeutics
Barinthus Biotherapeutics, founded in 2016, is a United Kingdom-based clinical-stage biopharmaceutical company that is innovating in the realms of Biotechnology, Health and Wellness, and Pharmaceutical industries. The company specializes in developing novel T-cell immunotherapeutic candidates aimed...
We will tell you when either one moves
BounceWatch watches Outpace Bio and Barinthus Biotherapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Outpace Bio and Barinthus Biotherapeut... — by email.
Frequently Asked Questions
Compare Outpace Bio with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Outpace Bio on 15 Jun 2026, and Barinthus Biotherapeutics on 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.